Cellectar Biosciences
CLRB
11 hedge funds and large institutions have $413K invested in Cellectar Biosciences in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.03% less ownership
Funds ownership: 0.06% → 0.03% (-0.03%)
15% less funds holding
Funds holding: 13 → 11 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
70% less capital invested
Capital invested by funds: $1.37M → $413K (-$961K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$103K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$34.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$7.83K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$4.27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WC
Wexford Capital
West Palm Beach,
Florida
|
-$750K |
| 2 |
VCM
Vigilant Capital Management
Portland,
Maine
|
-$6K |
| 3 |
Renaissance Technologies
New York
|
-$3.56K |
| 4 |
IGGA
Iron Gate Global Advisors
Nsl,
Utah
|
-$2K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$712 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SFM
1
Sphera Funds Management
Tel Aviv,
Israel
| $136K | – | – | – |
|
|
2
Morgan Stanley
New York
| $102K | +$103K | +145 | +193% |
|
|
3
Renaissance Technologies
New York
| $88K | -$3.56K | -5 | -3% |
|
4
Vanguard Group
Malvern,
Pennsylvania
| $26K | – | – | – |
|
|
5
Citadel Advisors
Miami,
Florida
| $23K | +$34.9K | +49 | New |
|
6
Dimensional Fund Advisors
Austin,
Texas
| $16K | – | – | – |
|
|
7
UBS Group
Zurich,
Switzerland
| $9K | +$7.83K | +11 | +138% |
|
|
AIC
8
AWM Investment Company
New York
| $5K | – | – | – |
|
9
US Bancorp
Minneapolis,
Minnesota
| $4K | – | – | – |
|
|
LTFS
10
Ladenburg Thalmann Financial Services
Miami,
Florida
| $3K | +$4.27K | +6 | New |
|
|
SIM
11
Sonora Investment Management
Tucson,
Arizona
| $1K | – | – | – |
|
|
WC
12
Wexford Capital
West Palm Beach,
Florida
| – | -$750K | -1,125 | Closed |
|
|
VCM
13
Vigilant Capital Management
Portland,
Maine
| – | -$6K | -7 | Closed |
|
|
IGGA
14
Iron Gate Global Advisors
Nsl,
Utah
| – | -$2K | -3 | Closed |
|
|
15
Bank of America
Charlotte,
North Carolina
| – | -$712 | -1 | Closed |
|
CLRB Hedge Fund Activity: Q4 2018 in Review
11 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q4 2018, worth a combined $413K — down 70% from $1.37M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CLRB and 2 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Morgan Stanley, adding an estimated $103K. The largest seller was Wexford Capital, exiting entirely with an estimated $750K sold.
- 11 institutional investors held Cellectar Biosciences (CLRB) as of Q4 2018, down from 13 in Q3 2018.
- Funds reported $413K of Cellectar Biosciences stock for Q4 2018, down 70% quarter-over-quarter.
- 2 funds opened new Cellectar Biosciences positions in Q4 2018 and 4 closed out, a net change of -2 holders.
- The largest Cellectar Biosciences buyer in Q4 2018 was Morgan Stanley, an estimated $103K added.
- The largest Cellectar Biosciences seller in Q4 2018 was Wexford Capital, an estimated $750K sold.
Based on aggregated 13F filings for Q4 2018.